Jupiter Life Line Hospitals Ltd
NSE: JLHL BSE: 543980Healthcare
Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.[1]
₹1,363
52W: ₹1152 — ₹1625
PE 45.9 · Book ₹245 · +456% vs bookMarket Cap₹8,937 Cr
Stock P/E45.9Price to Earnings
ROCE15.6%Return on Capital
ROE12.8%Return on Equity
Div. Yield0.08%Face Value ₹10
Strengths
- +Company has delivered good profit growth of 63.6% CAGR over last 5 years
Weaknesses
- −Working capital days have increased from 36.2 days to 136 days
Shareholding Pattern
Promoters40.91%
FIIs8.48%
DIIs17.01%
Public33.6%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 40.91% | 40.91% | 40.91% | 40.91% | 40.91% | 40.91% | 40.91% | 40.91% |
| FIIs | 6.06% | 8.84%▲2.8 | 10.04%▲1.2 | 10.04% | 9.77%▼0.3 | 9.06%▼0.7 | 8.48%▼0.6 | 8.48% |
| DIIs | 13.85% | 13.46%▼0.4 | 15.75%▲2.3 | 15.64%▼0.1 | 15.82%▲0.2 | 16.97%▲1.1 | 17.44%▲0.5 | 17.01%▼0.4 |
| Public | 39.18% | 36.79%▼2.4 | 33.31%▼3.5 | 33.43%▲0.1 | 33.51%▲0.1 | 33.08%▼0.4 | 33.17%▲0.1 | 33.6%▲0.4 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 230 | 246 | 241 | 275 | 270 | 274 | 278 | 316 | 291 | 312 |
| Expenses | 173 | 189 | 184 | 204 | 202 | 202 | 210 | 237 | 216 | 234 |
| Operating Profit | 57 | 57 | 57 | 71 | 69 | 72 | 68 | 79 | 76 | 78 |
| OPM % | 25% | 23% | 24% | 26% | 25% | 26% | 24% | 25% | 26% | 25% |
| Net Profit | 42 | 43 | 41 | 50 | 49 | 44 | 43 | 55 | 44 | 49 |
| EPS ₹ | 6.44 | 6.58 | 6.2 | 7.67 | 7.52 | 6.78 | 6.6 | 8.33 | 6.75 | 7.5 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹1,198Cr, up 13% YoY. OPM at 25%.
Debt Position
Borrowings at ₹335Cr. Debt-to-equity ratio: 0.22x. Healthy balance sheet.
Capex Cycle
CWIP at ₹113Cr (10% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 17.01% (+4.32pp change). FIIs: 8.48% (+3.86pp change). Promoters hold 40.91%.
Margin & Efficiency
ROCE improving from 0% (Mar 2018) to 16% (Mar 2026). Working capital days: 136.
Valuation
PE 45.9x with 15.6% ROCE. Price is 456% above book value of ₹245. Dividend yield: 0.08%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1d - Newspaper Publication for Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026
- Announcement under Regulation 30 (LODR)-Investor Presentation 2d - InvInvestor Presentation for the quarter and year ended March 31, 2026estor Presentation
- Corporate Action-Intimation of Sub division / Stock Split 2d - Q4/FY26 results approved; interim dividend Rs1/share, 1:5 stock split, and Dr. Ajay Thakker appointed Chairman & Whole Time Director.
- Announcement under Regulation 30 (LODR)-Change in Management 2d - Board approved FY26 results, 10% interim dividend (record date May 22), 1:5 split, and Dr. Ajay Thakker’s appointment.
- Declaration Of Interim Dividend 2d
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Rating update 10 Mar from icra